X
ALNY icon

Xponance’s Alnylam Pharmaceuticals ALNY Stock Holding History

Xponance’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.1M Buy
30,242
+371
+1% +$112K 0.06% 259
2026
Q1 		$9.88M Buy
29,871
+2,543
+9% +$865K 0.07% 223
2025
Q4 		$10.9M Buy
27,328
+1,176
+4% +$520K 0.08% 187
2025
Q3 		$11.9M Buy
26,152
+1,135
+5% +$462K 0.09% 171
2025
Q2 		$8.16M Buy
25,017
+1,860
+8% +$515K 0.07% 232
2025
Q1 		$6.25M Buy
23,157
+701
+3% +$180K 0.06% 251
2024
Q4 		$5.28M Buy
22,456
+1,806
+9% +$475K 0.05% 296
2024
Q3 		$5.68M Sell
20,650
-426
-2% -$111K 0.05% 274
2024
Q2 		$5.12M Buy
21,076
+1,378
+7% +$218K 0.05% 279
2024
Q1 		$2.94M Buy
19,698
+5,609
+40% +$936K 0.03% 420
2023
Q4 		$2.7M Sell
14,089
-895
-6% -$152K 0.03% 399
2023
Q3 		$2.65M Buy
14,984
+109
+0.7% +$20.8K 0.04% 382
2023
Q2 		$2.83M Sell
14,875
-1,963
-12% -$389K 0.04% 374
2023
Q1 		$3.37M Buy
16,838
+161
+1% +$33.8K 0.05% 331
2022
Q4 		$3.96M Buy
16,677
+2,352
+16% +$502K 0.06% 279
2022
Q3 		$2.87M Buy
14,325
+22
+0.2% +$4.2K 0.06% 308
2022
Q2 		$2.09M Buy
14,303
+520
+4% +$73.8K 0.04% 364
2022
Q1 		$2.25M Buy
13,783
+387
+3% +$59K 0.04% 348
2021
Q4 		$2.27M Buy
13,396
+9
+0.1% +$1.67K 0.04% 348
2021
Q3 		$2.53M Sell
13,387
-326
-2% -$61.2K 0.05% 304
2021
Q2 		$2.33M Buy
13,713
+1,658
+14% +$243K 0.04% 331
2021
Q1 		$1.7M Sell
12,055
-24
-0.2% -$3.61K 0.04% 352
2020
Q4 		$1.57M Buy
12,079
+114
+1% +$15.2K 0.03% 356
2020
Q3 		$1.74M Buy
11,965
+137
+1% +$19.5K 0.04% 310
2020
Q2 		$1.75M Buy
+11,828
New +$1.59M 0.05% 285

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Xponance's ALNY Position: Q2 2026 in Review

Xponance increased its Alnylam Pharmaceuticals (ALNY) stake by 1.2% in Q2 2026, buying an estimated $112K and bringing the position to 30,242 shares worth $9.1M. The position accounts for 0.06% of the portfolio, ranked #259.

Xponance first reported a position in ALNY in Q2 2020 and has held it in 25 quarters since. The position peaked at $11.9M in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Xponance held 30,242 shares of Alnylam Pharmaceuticals worth $9.1M as of Q2 2026.
  • Xponance bought 371 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $112K.
  • Alnylam Pharmaceuticals made up 0.06% of Xponance's portfolio in Q2 2026, its #259 holding.
  • Xponance first reported a position in Alnylam Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Xponance's Alnylam Pharmaceuticals position peaked at $11.9M in Q3 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.